Emerging targets for the treatment of scleroderma (Q34270856)

1 August 2017

Emerging targets for the treatment of scleroderma (English)

1 reference

1 August 2017

Andrew Leask

1

1 reference

PubMed ID

22533795

1 August 2017

language of work or name

English

0 references

publication date

25 April 2012

1 reference

Expert Opinion on Emerging Drugs

1 August 2017

1 reference

1 August 2017

17

1 reference

1 August 2017

2

1 reference

1 August 2017

173-179

1 reference

Targeted therapy comes of age in scleroderma

1 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Renal manifestations of systemic sclerosis--clinical features and outcome assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Matrix contraction by dermal fibroblasts requires transforming growth factor-beta/activin-linked kinase 5, heparan sulfate-containing proteoglycans, and MEK/ERK: insights into pathological scarring in chronic fibrotic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Targeting the TGFbeta, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Molecular subsets in the gene expression signatures of scleroderma skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Cell-mediated immunity in rheumatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Proteomic analysis of scleroderma lesional skin reveals activated wound healing phenotype of epidermal cell layer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Soluble TNF mediates the transition from pulmonary inflammation to fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Prostaglandin F(2alpha) receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Lack of tumor necrosis factor receptor type 1 inhibits liver fibrosis induced by carbon tetrachloride in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Upregulation of the p75 but not the p55 TNF-alpha receptor mRNA after silica and bleomycin exposure and protection from lung injury in double receptor knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

mPGES-1 null mice are resistant to bleomycin-induced skin fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Role of prostaglandins in fibroblast activation and fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Prostaglandin E2 as an inhibitory modulator of fibrogenesis in human lung allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Prostaglandin E₂ protects murine lungs from bleomycin-induced pulmonary fibrosis and lung dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

TGF-beta and TNF-alpha: antagonistic cytokines controlling type I collagen gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Commentary on a recent article-"A prostacyclin analogue, Iloprost, protects from bleomycin-induced fibrosis in mice" Zhu Y et al. Respir Res. 2010 Mar 20;11(1):34.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Effectiveness of etanercept in bleomycin-induced experimental scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Cutaneous chronic graft-versus-host disease does not have the abnormal endothelial phenotype or vascular rarefaction characteristic of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

New developments in localized scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Systemic and cell type-specific gene expression patterns in scleroderma skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

B cell block: is rituximab a new possible treatment for systemic sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Interleukin 6 and plasma cell neoplasias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Interleukin-6 and its relation to inflammation and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Actual status of antiinterleukin-1 therapies in rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Capillary regeneration in scleroderma: stem cell therapy reverses phenotype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: Application of a latent linear trajectory model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

Skin involvement in scleroderma--where histological and clinical scores meet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.678833

10.1517/14728214.2012.678833

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

22533795